New TALVEY® (talquetamab-tgvs) plus DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj) data demonstrate the strength of a bispecific combination in earlier-line relapsed or refractory multiple myeloma ...Middle East

TALVEY® plus DARZALEX FASPRO® with or without pomalidomide showed progression-free survival of up to 81% and overall survival of up to 89% at 24 months MonumenTAL-3 is the third positive study in recent months from Johnson & Johnson's bispecific portfolio and is the first Phase 3 study of...

Hence then, the article about new talvey talquetamab tgvs plus darzalex faspro daratumumab and hyaluronidase fihj data demonstrate the strength of a bispecific combination in earlier line relapsed or refractory multiple myeloma was published today ( Saturday 13/06/2026 - 01:39 PM ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.

Read More Details
Finally We wish PressBee provided you with enough information of ( New TALVEY® (talquetamab-tgvs) plus DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj) data demonstrate the strength of a bispecific combination in earlier-line relapsed or refractory multiple myeloma )

Also on site :

• San Antonio Spurs Canceling Knicks Fans’ Tickets for NBA Finals Game 5
• Country Star Makes Billboard Chart History With No. 1 Hit Song Lasting 28 Weeks
• Innoscience Secures Final Victory in Patent Lawsuit as China's Supreme Court Upholds Injunction Against Infineon GaN Products